VKTX / 2 Growth Stocks That Doubled in 2023 and Could Shoot 55% to 87% Higher, According to Wall Street

Viking Therapeutics is looking to profit from the expanding market for obesity drugs. The company's two leading candidates are currently in phase 2 cl more_horizontal

Viking Therapeutics (NASDAQ: VKTX ) stock is on the move Wednesday as the clinical-stage biopharmaceutical company reveals data from a clinical trial. more_horizontal

Viking Therapeutics (NASDAQ:VKTX) shares shot up 12% in overnight US trading as the drug developer revealed more impressive trial data from a treatmen more_horizontal

Viking Therapeutics Inc. VKTX, -0.37% shares rose in the extended session Tuesday after the biotech drug developer said data from an early stage clini more_horizontal

After positive mid-stage data, Eli Lilly seems to have a chance at achieving best-in-class status in the valuable weight loss market. Viking's shares more_horizontal

A top competitor announced plans to move forward with a late-stage weight loss candidate today. Viking's weight-loss candidate is several years behind more_horizontal

Viking Therapeutics has a few drugs that have the potential to generate billions in revenue. The problem is that they are in early-stage trials, so th more_horizontal

Viking Therapeutics is a biotech with multiple potential blockbuster drugs in its portfolio. Encouraging trial results have made investors bullish abo more_horizontal